Form D · Other Health Care
Tallac Therapeutics, Inc.
Burlingame, CA · CIK 0001819027
Offering snapshot reported Jul 22, 2021 · SEC filing
- Reported sold
- $61.6M Offering amount: $61.6M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2021 | Amendment | $61,616,192 | No comparison | Not reported | SEC filing |
| Jul 27, 2020 | Initial | $21,175,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-371827
Source: Form D, filed Jul 22, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christine Brennan | Director |
| Michael Carusi | Director |
| Isaac Cheng | Director |
| Ran Geng | Director |
| Corey Goodman | Director |
| Jaume Pons | Director |
| Hong Wan | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
866 Malcolm Road, Suite 100
Burlingame, CA, 94010
Burlingame, CA, 94010